肝细胞癌患者血清Dickopff 1水平对TACE治疗后预后的影响

doi:10.3969/j.issn.1672-5069.2020.05.029

摘要/Abstract

摘要： 目的探讨肝细胞癌患者血清Dickopff相关蛋白1(Dickopff-1)水平对TACE治疗后预后的影响。方法 2016年1月～2018年1月在我院住院经导管动脉化疗栓塞术(TACE)治疗的HCC患者90例,选择同期在我院进行健康体检者90例,慢性乙型肝炎(CHB)患者86例,乙型肝炎肝硬化患者81例,采用ELISA法检测血清Dickopff-1和AFP水平,对HCC患者进行为期24个月的随访,绘制研究对象受试者工作特征曲线(ROC)并计算曲线下面积(AUC),确定血清Dickopff-1和AFP诊断HCC的效能,应用Kaplan-Meier曲线进行生存分析。结果 HCC组血清Dickopff-1和AFP水平显著高于肝硬化组或CHB组【分别对(0.8±0.1)ng/ml和(12.3±3.0)ng/ml,P<0.05】或健康人【分别对(0.7±0.1)ng/ml和(11.5±2.5)ng/ml,P<0.05】; TACE治疗后HCC患者血清Dickopff-1水平降至(1.6±0.6)ng/ml(P<0.05);有癌栓的HCC患者血清Dickopff-1水平显著高于无癌栓患者;死亡患者血清Dickopff-1水平显著高于生存患者;血清Dickopff-1和AFP单独诊断HCC的AUC分别为0.860和0.618,对HCC都有一定的诊断价值( Z=6.297,P<0.05);血清Dickopff-1和AFP联合应用能提高诊断效能(AUC=0.892),其诊断的灵敏度、特异度和准确度均最高;Kaplan-Meier生存分析显示,高血清Dickopff-1水平患者总体生存率显著低于低水平组(x²=8.418,P<0.05)。结论 HCC患者血清Dickopff-1水平升高,其水平越高,在TACE治疗后预后越差,是否可以作为HCC患者在TACE治疗后疗效和预后判断的指标,值得研究。

关键词: 肝细胞癌, 经导管动脉化疗栓塞术, Dickopff 1, 预后 , ,

Abstract: Objective To investigate serum level of dickopff 1 in patients with hepatocellular carcinoma (HCC) and its impact on prognosis after transcatheter arterial chemoembolization (TACE) treatment. Methods 90 patients HCC, 90 healthy persons, 86 patients with chronic hepatitis B (CHB) and 81 patients with hepatitis B cirrhosis were enrolled in this study from January 2016 to January 2018, and all patients with HCC received TACE and followed-up for 24 months. Serum levels of Dickopff-1 and AFP were measured by ELISA. Serum Dickopff-1 levels in patients with different clinical and pathological characteristics were compared. The receiver operating characteristic curve (ROC) was drawn to determine the efficacy of serum Dickopff-1 and AFP in the diagnosis of HCC, and the Kaplan-Meier curve was applied for survival analysis. Results Serum Dickopff-1 and AFP levels in patients with HCC were significantly higher than those in patients with liver cirrhosis or in patients with CHB【(0.8±0.1)ng/ml and (12.3±3.0)ng/ml, P<0.05】 or in healthy persons 【(0.7±0.1)ng/ml and (11.5±2.5)ng/ml, respectively, P<0.05】; serum level of dickopff-1 in patients with HCC reduced after TACE treatment to (1.6±0.6)ng/ml, P<0.05); serum level of dickopff-1 in HCC patients with portal cancer thrombus was higher than that in patients without [(2.9±0.3) ng/ml vs. (2.1±0.5)ng/ml, P<0.05); serum level of dickopff-1 in dead patients was higher than that in survivals [(3.5±0.8) ng/ml vs. (1.2±0.3) ng/ml, P<0.05); the area under the ROC curve (AUC) of serum dickopff-1 or AFP alone in the diagnosis of HCC were 0.860 and 0.618, respectively, which had certain diagnostic value for HCC (Z=6.297, P<0.05) and the combined diagnosis of dickopff-1 and AFP improved the efficacy (AUC=0.892), and the sensitivity, specificity and accuracy of the diagnosis were all the highest; the Kaplan-Meier survival analysis showed that the overall survival of patients with high serum dickopff-1 levels was poorer than that in patients with low serum levels (x²=8.418, P<0.05). Conclusion Serum dickopff-1 levels increase in patients with HCC. The higher the levels of serum dickopff-1 in patients with HCC, the worse the prognosis. It might be used as an indicator of the efficacy and prognosis after TACE treatment in patients with HCC.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Dickopff 1, Prognosis

鲁斌, 程敏. 肝细胞癌患者血清Dickopff 1水平对TACE治疗后预后的影响[J]. 实用肝脏病杂志, 2020, 23(5): 719-722.

Lu Bin, Cheng Min.. Serum level of dickopff 1 in patients with hepatocellular carcinoma and its impact on prognosis after TACE treatment[J]. Journal of Practical Hepatology, 2020, 23(5): 719-722.

参考文献

[1] Lin P, Wen DY, Chen G,et al. Predictive value of hypoxia, metabolism and immune factors for prognosis in hepatocellular carcinoma: a retrospective analysis and multicenter validation study. J Cancer, 2020, 11(14):4145-4156.
[2] MengXC, Chen BH, Huang JJ, et al. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World J Gastroenterol, 2018, 24(4):484-493.
[3] Tellapuri S, Sutphin PD, Beg MS, et al. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol, 2018, 37(6):481-491.
[4] Jiang YL, Shang MM, Dong SZ,et al. Abnormally expressed circular RNAs as novel non-invasive biomarkers for hepatocellular carcinoma: a meta-analysis. World J Gastrointest Oncol, 2019, 11(10):909-924.
[5] Watany M, Badawi R, Elkhalawany W, et al. Study of dickkopf-1 (dkk-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res, 2017, 11(2):32-34.
[6] Ye Y, Long X, Zhang L,et al. Nts/ntr1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the wnt/β-catenin signaling pathway in hepatocellular carcinoma. Oncotarget, 2016, 7(43):70303-70322.
[7] 李若坤,严福华.肝细胞癌国际诊断指南与国内诊疗规范的比较与解读.中华放射学杂志,2018,52(9):725-728.
[8] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版). 传染病信息, 2017, 16(7):705-720.
[9] 杨针,汪建林,尚润泽,等.术前血清甲胎蛋白水平与肝细胞癌术后患者早期复发的相关性分析.中华肝胆外科杂志,2018,24(3):179-183.
[10] Jin SY, Jung YT.Construction of a replication-competent retroviral vector for expression of the vsv-g envelope glycoprotein for cancer gene therapy. Arch Virol, 2020,165(5):1089-1097.
[11] Wang BL, Kou SB, Lin ZY, et al. Insights on the interaction mechanism of brigatinib to human α-1-acid glycoprotein: Experimental and computational approaches.Int J Biol Macromol, 2020,157:340-349.
[12] Cannon RE, Richards AC, Trexler AW, et al. Effect of genx on p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 at the blood-brain barrier.Environ Health Perspect,2020,128(3):37002.
[13] Wang Y,Liao X,Ye Q, et al. Clinic implication of muc1 o-glycosylation and c1galt1 in esophagus squamous cell carcinoma. Sci China Life Sci, 2018, 61(11):1389-1395.
[14] Du T, Jia X, Dong X,et al. Cosmc disruption-mediated aberrant o-glycosylation suppresses breast cancer cell growth via impairment of cd44. Cancer Manag Res, 2020, 12:511-522.
[15] N Zekri AR, El Kassas M, Salam ESE, et al. The possible role of dickkopf-1, golgi protein- 73 and midkine as predictors of hepatocarcinogenesis: a review and an egyptian study. Sci Rep, 2020, 10(1):5156.
[16] Corey F, Mandy T, Emilie W, et al. Fp395 sclerostin and dkk-1 are associated with measured gfr and disease biomarkers in ckd-mbd. Nephrol Dial Transpl,2018, 33(1):i167-i167.
[17] Jaschke N, Hofbauer LC, Gbel A, et al. Evolving functions of dickkopf-1 in cancer and immunity. Cancer Lett, 2020, 482:1-7.
[18] Jang ES, Choi YS, Leissner P, et al. Performance of biomarkers for diagnosis of hepatocellular carcinoma–alpha fetoprotein, protein induced by vitamin K absence, osteopontin and dickkopf-1. PLoS One, 2014, 11(3):e0151069.
[19] 陈永其,陈前,袁春艳,等.肝细胞癌癌组织和癌旁肝组织Ep-CAM和C-Kit表达及其意义探讨.实用肝脏病杂志,2019,22(1):109-112.
[20] Fouad YM, Mohamed HI, Kamal EM, et al. Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma. Scand J Gastroenterol, 2016,51(9):1135-1137.